Functionalized graphene substrates
The present invention is generally directed to functionalized graphene substrates, methods of making such substrates and methods of using such substrates. In one aspect, the present invention provides a graphene substrate. The substrate comprises edge and non-edge regions, and organic or inorganic molecules are bound to the edge regions of the substrate. The organic or inorganic molecules are present on the substrate edges at a population greater than about one molecule per 10,000 nm.
1. A graphene substrate, wherein the substrate comprises edge and non-edge regions, and wherein organic or inorganic molecules are bound to a nucleophilic moiety covalently linked to a carbon molecule in the edge regions of the substrate, and wherein the organic or inorganic molecules are present on the substrate edges at a population greater than about one molecule per 10,000 nm.
2. The graphene substrate according to claim 1 , wherein organic molecules are present on the substrate, and wherein the organic molecules are selected from a group consisting of: antibodies; antibody fragments; aptamers; large molecule therapeutics; oligonucleotides; oligopeptides; oligopeptides, proteins and small molecule therapeutics.
3. The graphene substrate according to claim 2 , wherein the population is greater than about 10 molecules per 10,000 nm.
4. The graphene substrate according to claim 3 , wherein the organic molecules are selected from a group consisting of: antibodies; antibody fragments; proteins; and, aptamers.
5. The graphene substrate according to claim 3 , wherein the organic molecules are selected from a group consisting of: large molecule therapeutics; oligonucleotides; oligopeptides; oligopeptides and small molecule therapeutics.
6. The graphene substrate according to claim 4 , wherein the population is greater than about 50 molecules per 10,000 nm 2 .
7. The graphene substrate according to claim 5 , wherein the population is greater than about 50 molecules per 10,000 nm 2 .
8. The graphene substrate according to claim 6 , wherein the organic molecules are proteins, and wherein the proteins are selected from a group consisting of: Insulin; Pramlintide; Growth hormone; Mecasermin; Factor VIII; Factor IX; Antithrombin III; Protein C; B-Gluco-cerebrosidase; Alglucosidase-α; Laronidase; Idursulphase; Galsulphase; Agalsidase-β; A-1-Proteinase inhibitor; Lactase; Lipase; Amylase; Protease; Adenosine deaminase; Human albumin; Erythropoietin; Darbepoetin-α; Filgrastim; Sargramostim; Oprelvekin; Human follicle-stimulating hormone; Human chorionic gonadotropin; Lutropin-α; Type I α-interferon; Interferon-α2a; Interferon-α2b; Interferon-αn3; Interferon-β1a; Interferon-β1; Interferon-γ1; Aldesleukin; Alteplase; Reteplase; Tenecteplase; Urokinase; Factor VIIa; Drotrecogin-α; Salmon calcitonin; Teriparatide; Exenatide; Octreotide; Dibotermin-α; Recombinant human bone morphogenic protein 7; Histrelin; Palifermin; Becaplermin; Trypsin; Nesiritide; Botulinum toxin type A; Botulinum toxin type B; Collagenase; Human deoxy-ribonuclease I; Hyaluronidase; Papain; L-Asparaginase; Rasburicase; Lepirudin; Bivalirudin; Streptokinase; Anistreplase; Bevacizumab; Cetuximab; Panitumumab; Alemtuzumab; Rituximab; Trastuzumab; Abtacept; Anakinra; Adalimumab; Etanercept; Infliximab; Alefacept; Efalizumab; Natalizumab; Eculizumab; Antithymocyte globulin; Basiliximab; Daclizumab; Muromonab-CD3; Omalizumab; Palivizumab; Enfuvirtide; Abciximab; Pegvisomant; Crotalidae polyvalent immune Fab; Digoxin immune serum Fab; Ranibizumab; Denileukin diftitox; Ibritumomab tiuxetan; Gemtuzumab ozogamicin; Tositumomab.
9. A method of functionalizing a graphene substrate, wherein the method comprises the steps of:
a) obtaining a graphene substrate that has edge regions and non-edge regions, wherein the edge regions comprise carboxylic acid moieties, epoxy moieties or hydroxyl moieties;
b) reacting the carboxylic acid moieties, epoxy moieties or hydroxyl moieties with a Nu-M, wherein Nu is a nucleophilic moiety and M is an attached organic or inorganic moiety,
thereby functionalizing the graphene substrate.
10. The method according to claim 9 , wherein edge regions comprise carboxylic acids.
11. The method according to claim 9 , wherein Nu is NH 2 , and wherein M is an attached organic moiety, and wherein the organic moiety is selected from a group of organic moieties consisting of: an antibody; a linking group attached to an antibody; an antibody fragment; a linking group attached to an antibody fragment; a linking group attached to an aptamer; a protein; a linking group attached to a protein; an oligopeptide; a linking group attached to an oligopeptide; a linking group attached to an oligosaccharide; a large molecule therapeutic; a linking group attached to a large molecule therapeutic; a small molecule therapeutic; a linking group attached to a small molecule therapeutic.
12. The method according to claim 11 , wherein the organic molecule is a linking group attached to a protein, and wherein the protein is selected from a group consisting of: Insulin; Pramlintide; Growth hormone; Mecasermin; Factor VIII; Factor IX; Antithrombin III; Protein C; B-Gluco-cerebrosidase; Alglucosidase-α; Laronidase; Idursulphase; Galsulphase; Agalsidase-β; A-1-Proteinase inhibitor; Lactase; Lipase; Amylase; Protease; Adenosine deaminase; Human albumin; Erythropoietin; Darbepoetin-α; Filgrastim; Sargramostim; Oprelvekin; Human follicle-stimulating hormone; Human chorionic gonadotropin; Lutropin-α; Type I α-interferon; Interferon-α2a; Interferon-α2b; Interferon-αn3; Interferon-β1a; Interferon-β1b; Interferon-γ1; Aldesleukin; Alteplase; Reteplase; Tenecteplase; Urokinase; Factor VIIa; Drotrecogin-α; Salmon calcitonin; Teriparatide; Exenatide; Octreotide; Dibotermin-α; Recombinant human bone morphogenic protein 7; Histrelin; Palifermin; Becaplermin; Trypsin; Nesiritide; Botulinum toxin type A; Botulinum toxin type B; Collagenase; Human deoxy-ribonuclease I; Hyaluronidase; Papain; L-Asparaginase; Rasburicase; Lepirudin; Bivalirudin; Streptokinase; Anistreplase; Bevacizumab; Cetuximab; Panitumumab; Alemtuzumab; Rituximab; Trastuzumab; Abtacept; Anakinra; Adalimumab; Etanercept; Infliximab; Alefacept; Efalizumab; Natalizumab; Eculizumab; Antithymocyte globulin; Basiliximab; Daclizumab; Muromonab-CD3; Omalizumab; Palivizumab; Enfuvirtide; Abciximab; Pegvisomant; Crotalidae polyvalent immune Fab; Digoxin immune serum Fab; Ranibizumab; Denileukin diftitox; Ibritumomab tiuxetan; Gemtuzumab ozogamicin; Tositumomab.
13. The method according to claim 12 , wherein the functionalized graphene substrate has a population of organic molecules at the edge region of at least 1 per 10,000 nm.
14. The method according to claim 13 , wherein the functionalized graphene substrate has a population of organic molecules at the edge region of at least 50 per 10,000 nm.